Compare CGEM & VINP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CGEM | VINP |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 780.4M | 807.6M |
| IPO Year | N/A | N/A |
| Metric | CGEM | VINP |
|---|---|---|
| Price | $12.10 | $12.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 2 |
| Target Price | ★ $28.80 | $14.00 |
| AVG Volume (30 Days) | ★ 676.1K | 49.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.93% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $69.11 |
| Revenue Next Year | N/A | $20.96 |
| P/E Ratio | ★ N/A | $24.24 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.68 | $8.66 |
| 52 Week High | $13.43 | $13.61 |
| Indicator | CGEM | VINP |
|---|---|---|
| Relative Strength Index (RSI) | 53.63 | 39.32 |
| Support Level | $11.40 | $12.07 |
| Resistance Level | $12.55 | $12.65 |
| Average True Range (ATR) | 0.87 | 0.42 |
| MACD | -0.11 | -0.04 |
| Stochastic Oscillator | 32.85 | 20.83 |
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.